×
About 596 results

ALLMedicine Drug Eruptions Center

Research & Reviews  267 results

Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib an...
https://www.ncbi.nlm.nih.gov/pubmed/32609449
Dermatology Online Journal; Shakhbazova A, Hinds B et. al.

Jul 1st, 2020 - Disseminated superficial actinic porokeratosis (DSAP) is an uncommon skin condition that can be inherited or may occur sporadically with multiple red-brown, thin plaques in a photodistribution. The condition more often affects middle-aged women an...

Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cut...
https://doi.org/10.1111/jcpt.13201
Journal of Clinical Pharmacy and Therapeutics REFERENCES; Huang W, Li J et. al.

Jun 1st, 2020 - Imatinib mesylate (IM) is the first-line therapy for unresectable or metastatic gastrointestinal stromal tumours (GISTs). Here, we report a case of successful progressive dose optimization by therapeutic drug monitoring (TDM) for a patient with GI...

The use of drug calendars for the diagnosis of cutaneous drug eruptions in the age of e...
https://www.ncbi.nlm.nih.gov/pubmed/32239886
Dermatology Online Journal; Cohen PR, Grossman ME

Apr 2nd, 2020 - A morbilliform drug eruption is the most common condition leading to a dermatology consultation for a patient in the hospital. Timing is an important diagnostic tool since the onset of a skin rash usually takes place within days-to-weeks of the st...

The life-threatening eruption in HIV and immunosuppression.
https://doi.org/10.1016/j.clindermatol.2019.10.014
Clinics in Dermatology; Ramos-E-Silva M, Secchin P et. al.

Mar 21st, 2020 - Immunosuppressed patients frequently have skin diseases of mild to moderate intensity. Diagnosis as well as treatment should be performed early to avoid important complications for these patients. Skin eruptions are among these problems. Life-thre...

Cytokines/Chemokines: Novel Biomarkers Associated with Severe Cutaneous Adverse Reactions.
https://doi.org/10.1089/jir.2019.0012
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research; Zhang X, Lu WS et. al.

Mar 20th, 2020 - Although the incidence of severe cutaneous adverse reactions (SCARs) is very low, if it is not diagnosed and treated in time, it can not only cause skin and mucous membrane involvement, but can also cause multiple organ failure and even death. The...

see more →

Guidelines  1 results

Genital Ulcers: Differential Diagnosis and Management
https://www.aafp.org/afp/2020/0315/p355.html
American Family Physician; Roett MA,et al

Mar 14th, 2020 - Genital ulcers may be located on the vagina, penis, and anorectal or perineal areas and may be infectious or noninfectious. Herpes simplex virus is the most common cause of genital ulcers in the United States. A diagnosis of genital herpes simplex...

see more →

Clinicaltrials.gov  283 results

Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib an...
https://www.ncbi.nlm.nih.gov/pubmed/32609449
Dermatology Online Journal; Shakhbazova A, Hinds B et. al.

Jul 1st, 2020 - Disseminated superficial actinic porokeratosis (DSAP) is an uncommon skin condition that can be inherited or may occur sporadically with multiple red-brown, thin plaques in a photodistribution. The condition more often affects middle-aged women an...

Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cut...
https://doi.org/10.1111/jcpt.13201
Journal of Clinical Pharmacy and Therapeutics REFERENCES; Huang W, Li J et. al.

Jun 1st, 2020 - Imatinib mesylate (IM) is the first-line therapy for unresectable or metastatic gastrointestinal stromal tumours (GISTs). Here, we report a case of successful progressive dose optimization by therapeutic drug monitoring (TDM) for a patient with GI...

The use of drug calendars for the diagnosis of cutaneous drug eruptions in the age of e...
https://www.ncbi.nlm.nih.gov/pubmed/32239886
Dermatology Online Journal; Cohen PR, Grossman ME

Apr 2nd, 2020 - A morbilliform drug eruption is the most common condition leading to a dermatology consultation for a patient in the hospital. Timing is an important diagnostic tool since the onset of a skin rash usually takes place within days-to-weeks of the st...

The life-threatening eruption in HIV and immunosuppression.
https://doi.org/10.1016/j.clindermatol.2019.10.014
Clinics in Dermatology; Ramos-E-Silva M, Secchin P et. al.

Mar 21st, 2020 - Immunosuppressed patients frequently have skin diseases of mild to moderate intensity. Diagnosis as well as treatment should be performed early to avoid important complications for these patients. Skin eruptions are among these problems. Life-thre...

Cytokines/Chemokines: Novel Biomarkers Associated with Severe Cutaneous Adverse Reactions.
https://doi.org/10.1089/jir.2019.0012
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research; Zhang X, Lu WS et. al.

Mar 20th, 2020 - Although the incidence of severe cutaneous adverse reactions (SCARs) is very low, if it is not diagnosed and treated in time, it can not only cause skin and mucous membrane involvement, but can also cause multiple organ failure and even death. The...

see more →

News  45 results

Genital Ulcers: Differential Diagnosis and Management
https://www.aafp.org/afp/2020/0315/p355.html
American Family Physician; Roett MA,et al

Mar 14th, 2020 - Genital ulcers may be located on the vagina, penis, and anorectal or perineal areas and may be infectious or noninfectious. Herpes simplex virus is the most common cause of genital ulcers in the United States. A diagnosis of genital herpes simplex...

Mogamulizumab prolongs PFS in CTCL
https://www.mdedge.com/hematology-oncology/article/184781/lymphoma-plasma-cell-disorders/mogamulizumab-prolongs-pfs-ctcl
HT Staff

Aug 14th, 2018 - Photo by Larry Young Youn Kim, MD Mogamulizumab is an effective treatment option for relapsed/refractory cutaneous T-cell lymphoma (CTCL), according to researchers. In the phase 3 MAVORIC trial, mogamulizumab prolonged progression-free survival (P.

Mogamulizumab is ‘valuable’ option for CTCL
https://www.mdedge.com/hematology-oncology/article/185146/lymphoma-plasma-cell-disorders/mogamulizumab-valuable-option-ctcl
Jen Smith

Feb 5th, 2018 - Photo by Larry Young Youn H. Kim, MD LA JOLLA, CA—Mogamulizumab is a valuable new therapeutic option for patients with cutaneous T-cell lymphoma (CTCL), according to researchers.

Levonorgestrel-Releasing Intrauterine System Causes a Lichenoid Drug Eruption
https://www.mdedge.com/dermatology/article/101017/dermatopathology/levonorgestrel-releasing-intrauterine-system-causes
Jennifer A. Jones Md, PhD, Marshall J. Shuler, MD et. al.

Jul 6th, 2015 - To the Editor: Numerous drugs have been implicated as possible causes of lichenoid drug eruptions (LDEs). We describe a case of an LDE secondary to placement of a levonorgestrel-releasing intrauterine system (IUS).

see more →